Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Fate Therapeutics, Inc. FATE

Healthcare  —  Biotechnology
2.35 0.02 0.86% as of 25 Sep
Market cap
$279.2M
P/E
0.0×
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Fate Therapeutics, Inc. (FATE) Business Profile

Updated before January 2025

Company Overview

Fate Therapeutics, Inc. (FATE) is a clinical-stage biopharmaceutical company dedicated to the development of cellular immunotherapies for cancer and immune disorders. Founded in 2007, the company is headquartered in San Diego, California. Fate Therapeutics was co-founded by Rudolf Jaenisch, a pioneer in stem cell research, and John D. Mendlein, a seasoned biotech executive. The company’s leadership team includes Scott Wolchko, who serves as the President and Chief Executive Officer, and other experienced professionals with deep expertise in biotechnology and immunotherapy.

Fate Therapeutics has established itself as a leader in the field of induced pluripotent stem cell (iPSC) technology. The company leverages its proprietary iPSC platform to develop off-the-shelf, engineered cellular immunotherapies that are designed to overcome the limitations of conventional donor-derived cell therapies. Fate Therapeutics is committed to advancing the science of cellular immunotherapy and improving outcomes for patients with life-threatening diseases.

Core Business Segments

Fate Therapeutics focuses on the development of cellular immunotherapies, with its core business segments categorized into the following areas:

1. iPSC-Derived NK Cell Therapies

Natural Killer (NK) cells are a type of immune cell that plays a critical role in the body’s defense against cancer and infections. Fate Therapeutics is developing a pipeline of iPSC-derived NK cell therapies that are engineered to enhance their anti-tumor activity. Key products in this category include:

  • FT516: An off-the-shelf NK cell therapy designed to target a wide range of cancers, including hematologic malignancies and solid tumors.
  • FT596: A first-of-its-kind, multi-antigen targeted NK cell therapy for the treatment of B-cell malignancies.

2. iPSC-Derived T Cell Therapies

Fate Therapeutics is also advancing a pipeline of iPSC-derived T cell therapies, which are engineered to target specific cancer antigens. These therapies are designed to overcome the challenges associated with donor variability and manufacturing scalability. Key products include:

  • FT819: The first-ever off-the-shelf, iPSC-derived CAR T-cell therapy targeting CD19, a protein commonly expressed on B-cell malignancies.

3. Preclinical Programs

In addition to its clinical-stage programs, Fate Therapeutics is actively pursuing preclinical research to expand its pipeline of cellular immunotherapies. The company is exploring new targets and engineering strategies to enhance the efficacy and safety of its therapies.

Business Model

Fate Therapeutics operates on a business model that integrates cutting-edge science, strategic partnerships, and a focus on scalability. The company’s approach includes:

  • Proprietary iPSC Platform: Fate Therapeutics uses its proprietary iPSC technology to create a renewable source of cellular immunotherapies. This platform enables the production of off-the-shelf therapies that are readily available for patients.
  • Strategic Collaborations: The company has established partnerships with leading biopharmaceutical companies, academic institutions, and research organizations to accelerate the development and commercialization of its therapies.
  • Revenue Generation: Fate Therapeutics generates revenue through collaboration agreements, licensing deals, and milestone payments. The company also plans to commercialize its therapies upon regulatory approval.

Strategic Direction

Fate Therapeutics is focused on advancing its pipeline of cellular immunotherapies and expanding its iPSC platform capabilities. Key strategic priorities include:

  • Clinical Development: The company is conducting multiple clinical trials to evaluate the safety and efficacy of its iPSC-derived NK and T cell therapies.
  • Pipeline Expansion: Fate Therapeutics is investing in preclinical research to identify new targets and develop next-generation cellular immunotherapies.
  • Manufacturing Innovation: The company is committed to enhancing its manufacturing processes to ensure the scalability and cost-effectiveness of its therapies.
  • Global Reach: Fate Therapeutics aims to expand its presence in international markets and make its therapies accessible to patients worldwide.

Competitive Landscape

Fate Therapeutics operates in a highly competitive biopharmaceutical industry, with several companies developing cellular immunotherapies. Key competitors include:

  • Kite Pharma (a Gilead Company): Focused on CAR T-cell therapies for cancer.
  • Novartis: A global leader in CAR T-cell therapy development.
  • Allogene Therapeutics: Specializes in allogeneic CAR T-cell therapies.
  • Bluebird Bio: Develops gene and cell therapies for severe genetic diseases and cancer.

Despite the competition, Fate Therapeutics differentiates itself through its proprietary iPSC platform and focus on off-the-shelf therapies.

Risk Factors

Fate Therapeutics faces several risks that could impact its business operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The development and approval of cellular immunotherapies are subject to stringent regulatory requirements.
  • Market Dependence: The company’s success is heavily dependent on the commercial viability of its therapies.
  • Supply Chain Disruptions: Any disruptions in the supply chain could affect the production and delivery of its therapies.
  • Competition: The biopharmaceutical industry is highly competitive, and new entrants or advancements by competitors could pose a threat.
  • Financial Risks: As a clinical-stage company, Fate Therapeutics relies on external funding and may face financial constraints.

Recent Developments

Fate Therapeutics has made significant progress in advancing its pipeline and expanding its capabilities. Recent developments include:

  • Clinical Trial Updates: The company has reported positive interim data from ongoing clinical trials of its iPSC-derived NK and T cell therapies.
  • Partnerships: Fate Therapeutics has entered into new collaboration agreements to accelerate the development of its therapies.
  • Manufacturing Expansion: The company has invested in state-of-the-art manufacturing facilities to support the production of its therapies.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of scalable and accessible therapies, reinforcing the value of Fate Therapeutics’ off-the-shelf approach.

Investment Considerations

Investors considering Fate Therapeutics should weigh the following strengths and risks:

Strengths

  • Innovative Technology: Proprietary iPSC platform with significant potential.
  • Strong Pipeline: Diverse portfolio of clinical and preclinical programs.
  • Strategic Partnerships: Collaborations with leading organizations.
  • Market Potential: Growing demand for cellular immunotherapies.

Risks

  • Clinical and Regulatory Risks: Uncertainty in clinical trial outcomes and regulatory approvals.
  • Financial Dependence: Reliance on external funding and potential dilution of shares.
  • Competitive Pressure: Intense competition in the biopharmaceutical industry.

Conclusion

Fate Therapeutics is at the forefront of cellular immunotherapy innovation, leveraging its proprietary iPSC platform to develop off-the-shelf therapies for cancer and immune disorders. With a strong pipeline, strategic partnerships, and a commitment to advancing the science of cellular immunotherapy, the company is well-positioned for future growth. However, investors should carefully consider the risks associated with clinical-stage biopharmaceutical companies. Overall, Fate Therapeutics represents a promising opportunity in the rapidly evolving field of cellular immunotherapy.